<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772329</url>
  </required_header>
  <id_info>
    <org_study_id>12031901</org_study_id>
    <nct_id>NCT01772329</nct_id>
  </id_info>
  <brief_title>Preoperative Cognitive Therapy for Improving Health Outcomes After TKA in High-risk Catastrophizing Subjects</brief_title>
  <acronym>CT_TKA</acronym>
  <official_title>Preoperative Cognitive Therapy for Improving Health Outcomes After Total Knee Replacement in High-risk Catastrophizing Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized controlled trial to evaluate the effects of treatment&#xD;
      intended to reduce pain catastrophizing among patients reporting high pain catastrophizing&#xD;
      prior to total knee replacement(TKR), total hip replacement(THR), or shoulder surgery in an&#xD;
      effort to thereby reduce the incidence of persistent post-surgical pain (PPP) and enhance&#xD;
      physical function at 3-months post-surgery. Preemptive treatment aimed at a known predictor&#xD;
      of PPP following total knee replacement is highly innovative and have potentially high impact&#xD;
      for public health. Cognitive therapy is a well-tolerated modality among chronic pain patients&#xD;
      with few if any side effects. Cognitive therapy (CT) represents an inexpensive method that&#xD;
      could greatly reduce suffering and costly post-surgical pain management for high risk TKR&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1 is to determine which CT protocol is most effective in reducing Pain Catastrophizing&#xD;
      Scale (PCS) and Coping Strategies Questionnaire Catastrophizing Subscale (CSQ-CAT) scores in&#xD;
      high-risk TKR candidates. CT will consist of four-to-eight weekly 1-hr individual cognitive&#xD;
      therapy sessions prior to surgery.&#xD;
&#xD;
      Aim 2 is to compare the most efficient treatment from Aim 1 with a control group to evaluate&#xD;
      pain relief at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>n=80 Subjects for Aim 1 and another n=80 Subjects for Aim 2</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Aim 1) Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>4 or 8 weeks after start of treatment</time_frame>
    <description>Pain Catastrophizing Scale - Min=0, Max=52, Higher score = more catastrophizing so lower scores are preferable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Aim 2) Proportion of patients with pain relief</measure>
    <time_frame>3 month</time_frame>
    <description>Proportion of patients w a 3 month decrease in WOMAC pain subscale &lt;= 4. (WOMAC Osteoarthritis Index)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-8)</measure>
    <time_frame>4 and 8 weeks after start of treatment</time_frame>
    <description>Patient Health Questionnaire (PHQ-8): The eight-item Patient Health Questionnaire depression scale (PHQ-8) is established as a valid diagnostic and severity measure for depressive disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized anxiety disorder (GAD-7)</measure>
    <time_frame>4 and 8 weeks after start of treatment</time_frame>
    <description>Generalized anxiety disorder (GAD-7): The seven-item Generalized Anxiety Disorder Scale (GAD-7) is a practical self-report anxiety questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Catastrophization</condition>
  <arm_group>
    <arm_group_label>4 weekly CT sessions - in person</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 weekly CT sessions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/&quot;Skype&quot;. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use &quot;Skype&quot;. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 weekly CT sessions - Tele-video</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/&quot;Skype&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routine care; no CT sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Therapy</intervention_name>
    <description>CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.</description>
    <arm_group_label>4 weekly CT sessions - Tele-video</arm_group_label>
    <arm_group_label>4 weekly CT sessions - in person</arm_group_label>
    <arm_group_label>8 weekly CT sessions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine Care</intervention_name>
    <description>Routine Care. No Cognitive Therapy Intervention</description>
    <arm_group_label>Routine care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. undergoing standard primary TKR; THR or Shoulder Surgery&#xD;
&#xD;
          2. 18- 85 yrs of age;&#xD;
&#xD;
          3. Surgical joint is the primary source of patient's pain;&#xD;
&#xD;
          4. Patient agrees to preoperative visits and treatment, follow-up visits and treatment,&#xD;
             and to comply with the assessment tests;&#xD;
&#xD;
          5. Patient consents to standard anesthetic and analgesic protocol, with medical care as&#xD;
             deemed necessary by the anesthesiologist, and has no contraindications.&#xD;
&#xD;
          6. Patient has been diagnosed with osteoarthritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently using antidepressant medication or undergoing cognitive therapy;&#xD;
&#xD;
          2. chronic opioid use â‰¥ 10 mg/day of morphine equivalents within one wk prior to the&#xD;
             surgery, and duration of use &gt; 4 wks;&#xD;
&#xD;
          3. history of opioid abuse;&#xD;
&#xD;
          4. inability to understand and communicate with the investigators to complete the study&#xD;
             related questionnaires&#xD;
&#xD;
          5. patient is planning to undergo another elective joint procedure during the 6-mo period&#xD;
             of participation;&#xD;
&#xD;
          6. any co-morbidity which results in severe systemic disease limiting function {as&#xD;
             defined by the American Society of Anesthesiology (ASA) physical status classification&#xD;
             &gt; 3}.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asokumar Buvanendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Moric</last_name>
    <phone>312-942-2806</phone>
    <email>mario_moric@rush.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Moric</last_name>
      <phone>312-942-2806</phone>
      <email>mario_moric@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Asokumar Buvanendran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Asokumar Buvanendran</investigator_full_name>
    <investigator_title>Profesor Anesthesiology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data as of yet but may be willing to.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

